Table 1.
HSPs | Pathophysiological processes | Potential mechanisms | The induction location | Effect and roles | Related agents | Reference | |
---|---|---|---|---|---|---|---|
Subarachnoid haemorrhage | |||||||
HSP70 (including GRP78) | Cerebral vasospasm, neural cell apoptosis, immunoreaction and inflammation | Refold protein, degrade damaged proteins, inhibit apoptosis, mediate BBB disruption and cell death via aberrant proteolysis | Bilateral neocortex, hippocampus, thalamus, septum, hypothalamus, caudoputamen and basal forebrain | Neuroprotective molecule, significant marker for cellular stress or damage; crucial predictor of poor prognosis; blood biomarker for the early differential diagnosis of haemorrhagic stroke and ischemic stroke | Geranylgeranylacetone, modified HSP70 proteins (eg TAT‐Hsp70), valproic acid, atorvastatin, | 12, 14, 15, 16, 17, 22, 24, 25, 28, 31, 33, 34, 35, 36, 37, 38, 40, 41, 50, 51, 52, 53, 54, 55, 56, 57, 58, 96, 97, 98 | |
HO‐1 | Cerebral vasospasm, lipid peroxidation | Metabolize haeme, remove haeme and iron, diastolic vascular smooth musclea | Microglia and cerebral blood vessels | Possible neuroprotective moleculeb; marker of cellular stress and damage in infarcted regions | Nicaraven, argon, carnosol, ebselen and CGS26393, HO‐1 protein combined with protein transduction domains | 14, 39, 40, 61, 62, 63, 64, 65, 66, 70, 71, 99, 100, 101 | |
HSP20 and HSP27 | Cerebral vasoconstriction, apoptosis pathway | Solubilize misfolded proteins and hinder their aggregation, suppress cell death signaling and protect neurons against ischemic injury | Astrocytes in the ischaemic zone and the ischaemic penumbra | Important molecules in cerebral vasoconstriction without ATP necessarily involved in the function | AZX100 | 14, 28, 40, 73, 74, 75, 76, 77, 78 | |
HSP90 | Apoptosis, inflammation, and BBB destruction | Stabilize and promote the function of P2X7 receptor, which is abundant in the nervous system and is associated with the pathophysiological process of inflammation and oxidative stress in EBI | Microglia and neurons of the hippocampus | Neurotoxic factor in the development of EBI | 17‐allylamino‐17‐demethoxygeldanamycin, A438079 | 79, 80, 81, 82, 83, 84, 85 | |
Intracerebral haemorrhage | |||||||
HO‐1 | Inflammation, oxidative stress and cytotoxicity | Increase oxidative stress, accelerate the accumulation of iron overload, promote inflammation and increase secondary injury | Microglia and cerebral blood vessels | Possible harmful moleculeb | Haemin, nicotinamide mononucleotides, minocycline | 14, 20, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 134, 144, 145, 146 | |
HSP70 | GRP75 | Neural cell apoptosis, immunoreaction | Inhibit inflammation and neuronal apoptosis | Mainly located in mitochondria, reduced after intracerebral haemorrhage | Neuroprotective molecule | Minocycline, geranylgeranylacetone, geldanamycin, Di Dang Tang | 36, 135, 136, 137, 138, 139, 140, 147, 148, 149, 150 |
GRP78 | Neural cell apoptosis | Inhibit neuronal apoptosis | Mainly located in endoplasmic reticulum | Neuroprotective molecule |
Abbreviations: BBB, blood‐brain barrier; EBI, early brain injury; GRP75, glucose‐regulated protein 75; GRP78, glucose‐regulated protein 78; HO‐1, haeme oxygenase‐1; HSP, heat shock protein; TAT, N‐terminal transactivator of transcription.
Carbon monoxide, one of the haeme metabolite, can up‐regulate soluble guanylyl cyclase, which contributes to cyclic guanosine monophosphate accumulation and subsequently leads to vascular smooth muscle relaxation.
The role of HO‐1 is still controversial, the overall effect of HO‐1 in SAH and ICH tends to be protective and harmful respectively.